Navigation Links
Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing
Date:11/9/2009

SOUTH SAN FRANCISCO, Calif., Nov. 9 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that on November 5, 2009, it received a letter from The NASDAQ Stock Market LLC ("Nasdaq") stating that the Nasdaq Hearing Panel has granted Anesiva's request for continued listing on The NASDAQ Global Market subject to the condition that Anesiva shall have completed on or before December 31, 2009, the proposed merger (the "Merger") contemplated by the Agreement and Plan of Merger, dated August 4, 2009, among Anesiva, Arca Acquisition Corporation ("Arca"), a wholly-owned subsidiary of Anesiva, Arcion Therapeutics, Inc. ("Arcion") and, with respect to Articles V and IX only of the agreement, each of the Arcion stockholders listed on Schedule I thereto.

On October 30, 2009, Anesiva announced that the Anesiva 2009 Annual Meeting of Stockholders will be held on December 3, 2009 at 9:00 a.m. PST at 400 Oyster Point, Suite 107A, South San Francisco, California. Stockholders of record at the close of business on October 9, 2009 will be eligible to vote at the 2009 Annual Meeting of Stockholders, at which the proposed Merger will be considered and voted upon. The definitive proxy statement for the 2009 Annual Meeting of Stockholders was mailed to stockholders on or about November 6, 2009.

About Anesiva

Anesiva seeks to be a leader in the development and commercialization of novel pharmaceutical products for pain management. Anesiva's lead product candidate is Adlea, a novel small molecule formulation of capsaicin that is currently in development for management of both acute and chronic pain. Adlea has been shown in clinical trials to provide extended pain relief after only a single administration in a variety of localized moderate-to-severe pain conditions.

Additional Information and Where to Find
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
2. Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
3. Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company
4. Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery
5. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
6. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
7. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
8. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
9. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
10. Anesiva Defines Regulatory Pathway for Adlea with FDA
11. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 Lazarus Effect, a medical device ... to facilitate removal of blood clots, announced the closing ... will support EU commercialization of several approved Lazarus Effect ... ReCover™ and Lazarus Cover™ in the United ... confidence in the value of our novel, platform technology ...
(Date:7/31/2014)... and VIENNA , July 31, ... a press conference in New York ... a vaccine against Parkinson,s disease. PD01A is the first therapy ... enter clinical testing. The Michael J. Fox Foundation ... 1.5 million grant, and presented at the press conference on ...
(Date:7/31/2014)... NORTHBROOK, Ill. , July 31, 2014 /PRNewswire/ ... as the head of corporate and employee communications ... to Jeff Winton , senior vice president, ... be responsible for developing and leading corporate brand ... business goals across North and South ...
Breaking Medicine Technology:Lazarus Effect Closes $5 Million Financing 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2
... ... research and biotechnology companies are testing 97 medicines and vaccines to ... report released today by the Pharmaceutical Research and Manufacturers of America ... - a global awareness campaign that originated at the 1988 World ...
... , XI,AN, China, Nov. ... a leading developer and producer,of plant extracts and pharmaceutical raw ... China, today reported that in its,third quarter, the company realized ... Revenues for the quarter ended Sept. 30, 2009 were $4,465,770, ...
Cached Medicine Technology:New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 2New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 3Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 2Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 3Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 4
(Date:7/31/2014)... Ohio (PRWEB) July 31, 2014 In ... that the pharmaceutical giant, Johnson & Johnson, is withdrawing ... it can spread undetected cancer. This important story ... (7/30), USA Today (7/31), the AP (7/30), the Pittsburgh ... morcellator tool is used during uterine procedures to, “slice ...
(Date:7/31/2014)... , Rest assured, there is a happy ending, ... shows that many college students are stressed out and ... there are simple ways for students to relieve stress ... of UC,s Health Promotion and Education Program. The trouble ... a whole array of different stress-management techniques college students ...
(Date:7/31/2014)... July 31, 2014 The Never Give Up ... supporters from11:00am-11:00pm on August 7th. Simply bring your ticket ... great food and beverages with friends and family. ... His amazing passion and contagious optimism continues to impact ... positive attitude in effort to pursue a happy life was ...
(Date:7/31/2014)... The “Nucleic Acid Isolation and ... Magnetic bead based), Consumables & Instruments, by Application ... End users - Global Forecasts to 2018” provides ... challenges, opportunities, current market trends, and strategies impacting ... along with the estimates and forecasts of the ...
(Date:7/31/2014)... 2014 Ticket Down is a reputable ... in Santa Clara, California. Fans in the United States of ... the best club and national teams in the world. Coming off ... has become the best time to be a fan of soccer ... being held on American soil this year, as well as international ...
Breaking Medicine News(10 mins):Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 2Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 3Health News:Simple tips to fend off freak-outs 2Health News:Simple tips to fend off freak-outs 3Health News:Don't Forget To Mention Never Give Up 26 Foundation 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Mexico vs. Chile Tickets Levi’s Stadium: Ticket Down Slashes Ticket Prices for Chile vs. Mexico at Levi’s Stadium in Santa Clara, California on September 6th 2Health News:Mexico vs. Chile Tickets Levi’s Stadium: Ticket Down Slashes Ticket Prices for Chile vs. Mexico at Levi’s Stadium in Santa Clara, California on September 6th 3
... , MORRISTOWN, N.J., Aug. 28 Watson Pharmaceuticals, ... company, today announced that its subsidiary, Watson Laboratories, Inc., has ... Administration (FDA) on its Abbreviated New Drug Application (ANDA) for ... 17 and above, as well as for prescription use in ...
... risk, researchers say , FRIDAY, Aug. 28 (HealthDay News) ... flu puts 1.5 other people at risk over the three ... the conclusion of a new study published in the journal ... showing early symptoms of the flu needs to contact their ...
... , , DETROIT, ... The Parade Company will launch The Biggest Loser: Detroit Edition contest ... selected from approximately 200 applicants to compete in this 12-week weight ... "The Biggest Loser is one of the most popular programs, ...
... 28 Children,s Hospital of Pittsburgh of UPMC has been ... leader in its use of healthcare information technology among pediatric ... KLAS interviewed leaders at virtually every hospital in the United ... software to order and chart under an organized program sponsored ...
... FRIDAY, Aug. 28 (HealthDay News) -- Men, want to keep high ... the message from a Harvard study that found that whole grain ... health. Although this study is among men, data from the Women,s ... grains as a part of a prudent, balanced diet may help ...
... TSX: COM , , VANCOUVER, ... / TSX: COM) today announced that Dr. Christian Torp-Pedersen ... 2b clinical trial of vernakalant (oral) at the European ... Barcelona, Spain from August 29 to September 2, 2009. ...
Cached Medicine News:Health News:Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B(R) for Over-the-Counter Use 2Health News:Study Details Swine Flu Transmission Rates 2Health News:Study Details Swine Flu Transmission Rates 3Health News:WDIV-TV, Blue Cross Blue Shield of Michigan and The Parade Company Help Launch The Biggest Loser: Detroit Edition 2Health News:Children's Hospital of Pittsburgh of UPMC Recognized for Deepest Use of Electronic Health Records for a Pediatric Hospital in Nation 2Health News:Children's Hospital of Pittsburgh of UPMC Recognized for Deepest Use of Electronic Health Records for a Pediatric Hospital in Nation 3Health News:Whole Grains, Bran May Fight Hypertension in Men 2Health News:Whole Grains, Bran May Fight Hypertension in Men 3Health News:Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of Cardiology Congress 2009 2Health News:Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of Cardiology Congress 2009 3
7 mm curved blade. Round handle....
7 mm strong curved blade. Round handle....
3 mm diameter roller blade, 15 mm from angle to tip. Round handle....
No. 4. 0.75 mm wide x 5 mm long, lightly curved tip, offset to the left. Hexagonal handle....
Medicine Products: